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Background and purpose: We have reported previously that Waon therapy improves cardiac and
vascular function, and prognosis of patients with chronic heart failure (CHF). CHF is character-
ized by generalized sympathetic activation and parasympathetic withdrawal. The purpose of
this study was to evaluate the effect of Waon therapy on autonomic nervous activity in patients
with CHF.
Methods and subjects: Fifty-four patients with CHF, who were receiving conventional therapy
for CHF, were divided into Waon therapy and control groups. In the Waon therapy group, 27
patients were treated with medication and Waon therapy. In the control group, 27 patients
were treated with only conventional CHF therapy. Cardiac function including cardiac output
(CO) and left ventricular ejection fraction (LVEF) was evaluated by echocardiography. The heart
rate variability, such as the coefﬁcient of variation of RR intervals (CVRR), the low-frequency
(LF) component, high-frequency (HF) component, the LF norm [LF/(LF +HF)], and HF norm
[HF/(LF +HF)], were measured at admission and 4 weeks after treatment.
Results: Echocardiography demonstrated that CO and LVEF signiﬁcantly increased after 4 weeks
in the Waon therapy group, but did not change in the control group. In the Waon therapy
group, CVRR, HF, and HF norm signiﬁcantly increased 4 weeks after Waon therapy. In addi-
tion, the LF/HF ratio and LF norm signiﬁcantly decreased 4 weeks after Waon therapy. In
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contrast, these parameters remained unchanged in the control group. Moreover, the HF and HF
norm were signiﬁcantly higher, and the LF/HF ratio and LF norm were signiﬁcantly lower after 4
weeks of Waon therapy group than after 4 weeks of only conventional therapy.








































Body weight, blood pressure and heart rate were measured
at admission and 4 weeks after treatment. The cardio-ing parasympathetic and dec
© 2011 Japanese College of C
Introduction
The autonomic nervous system maintains stable hemody-
namics by controlling sympathetic and parasympathetic
nervous activity. It is well known that the autonomic ner-
vous system may contribute to pathological conditions such
as ischemic heart disease, arrhythmia, and congestive heart
failure, and inﬂuence the prognosis of these diseases [1—3].
In heart failure patients, activation of the sympathetic ner-
vous activity causes myocardial damage [4], and it is one of
the important prognostic predictors [5,6].
Heart rate variability (HRV), i.e., the amount of heart
rate ﬂuctuations around the mean heart rate, can be used
as a marker of the cardiorespiratory control system. It is a
valuable tool to investigate the sympathetic and parasym-
pathetic components of autonomic nervous function [7].
Previous studies suggest that a marked reduction of HRV is
found in patients with chronic heart failure (CHF) [8]. The
high-frequency component of HRV, a marker of parasym-
pathetic modulation, declined markedly from the early
asymptomatic stage of pacing-induced heart failure in a dog
model. The parasympathetic withdrawal occurred rapidly in
a parallel fashion with the decline in left ventricular con-
tractility [9].
We developed a thermal therapy with a 60 ◦C dry sauna,
and have been investigating the various effects of thermal
therapy such as improvement of hemodynamic parameters,
endothelial function, and clinical symptoms in many conges-
tive heart failure patients [10—15]. Furthermore, we have
demonstrated that repeated sauna treatment improves the
prognosis of CHF in humans [16] and hamsters [17]. Gener-
ally, thermal therapy at very high temperature was originally
used to treat localized cancer. However, the therapy we
developed to treat cardiovascular diseases is quite differ-
ent, in that it consists of systemic soothing warmth that
comfortably refreshes the mind and body. Therefore, we
have changed the name from thermal to Waon therapy, since
‘‘Waon’’ in Japanese means soothing warmth [18—20]. To
date, we have performed Waon therapy in several hundred
CHF patients without any severe adverse effects.
We hypothesize that Waon therapy may improve auto-
nomic nervous function of CHF patients. Thus, the purpose
of this study was to evaluate the effect of Waon therapy on
autonomic nervous activity in patients with CHF.
Methods
Study populationFifty-four patients (38 men, 16 women) who had been
referred to Kagoshima University Hospital for treatment of
CHF were prospectively randomized into Waon therapy and





lng sympathetic nervous activity in patients with CHF.
ology. Published by Elsevier Ltd. All rights reserved.
reated with medications for heart failure at admission of
his study. In the Waon therapy group, 27 patients were
reated with medication and Waon therapy. In the control
roup, 27 patients continued the conventional medications
or CHF.
Inclusion criteria were New York Heart Association
NYHA) functional class II—IV and left ventricular ejection
raction (LVEF) < 50% on echocardiography. Exclusion cri-
eria were the presence of severe aortic valve stenosis,
ypertrophic cardiomyopathy with severe obstruction, CHF
reated with catecholamines, and renal failure requiring
emodialysis. We also excluded patients with excessive arti-
acts in the HRV analysis such as atrial ﬁbrillation, frequent
trial or ventricular premature contractions, marked repo-
arization abnormalities, and implantation of a pacemaker.
Informed consent was obtained from all of the patients
rior to participation, and the protocol was approved by
he Ethics Committee of the Faculty of Medicine, Kagoshima
niversity.
tudy protocol
atients in the Waon therapy group received medications for
eart failure and 20 sessions of Waon therapy (once a day,
days a week for 4 weeks). Patients in the control group
eceived conventional treatment for heart failure including
est, oxygen administration, and medication for 4 weeks in
he hospital. All examinations were performed at admission
nd 4 weeks after treatment.
aon therapy
aon therapy [18—20], a form of thermal therapy, uses a far
nfrared-ray dry sauna at 60 ◦C and differs from traditional
auna. Waon therapy has an absence of hydration pressure,
nd was performed as previously reported [10]. The patients
ere placed in a 60 ◦C sauna system for 15min; after leav-
ng the sauna, they underwent bed rest with a blanket to
eep them warm for an additional 30min. All patients were
eighed before and after the therapy, and oral hydration
ith water was used to compensate for weight loss due to
erspiration.
hysical examination and cardiac functionhoracic ratio (CTR) determined by chest radiography, and
chocardiography was performed at admission and 4 weeks
fter treatment. Cardiac output (CO), LVEF, left ventricular
nd-diastolic volume (LVEDV), and left and right ventricu-
ar Tei index (LV-, RV-Tei index) [21—23] were evaluated by
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Table 1 Baseline clinical characteristics.
Control group (n = 27) Waon therapy group (n = 27) p
Age (years) 64± 16 63± 15 0.76
Gender, M/F 19/8 19/8 1.00
NYHA functional class, II/III/IV 13/10/4 12/11/4 0.85
Etiology of heart failure, n (%)
DCM 12 (44%) 8 (30%) 0.25
ICM 10 (37%) 10 (37%) 1.00
Others 5 (19%) 9 (33%) 0.21
Complication, n (%)
Hypertension 9 (33%) 11 (41%) 0.57
Dyslipidemia 14 (52%) 16 (59%) 0.58
Diabetes mellitus 11 (41%) 12 (44%) 0.78
Current or past smoking 8 (30%) 12 (44%) 0.25
Medication, n (%)
ACE inhibitor 17 (63%) 14 (52%) 0.40
ARB 10 (37%) 13 (48%) 0.40
Beta-blocker 25 (93%) 25 (93%) 1.00
Statin 9 (33%) 11 (41%) 0.57
































































sValues are means± SD or n (%); ACE, angiotensin-converting enzym
ICM, ischemic cardiomyopathy; NYHA, New York Heart Association
chocardiography. All Doppler and echocardiographic mea-
urements were performed according to the guidelines of
he American Society of Echocardiography speciﬁed in 2005
24]. The LVEF and LVEDV were obtained by the modiﬁed
iplane Simpson’s method from the apical 2- and 4-chamber
iews. CO was calculated by the product of stroke vol-
me and heart rate. Stroke volume was obtained by the
V outﬂow Doppler method as the product of area and the
ime—velocity integral of LV outﬂow track. The Tei index,
he sum of isovolumic contraction and relaxation times
ivided by the ejection time, is a well-established good indi-
ator of global cardiac function [21,22]. It was obtained from
oppler recordings of LV and RV inﬂow and outﬂow.
aboratory examinations
fasting plasma blood sample was taken in the morn-
ng to measure plasma concentrations of neurohormones,
uch as catecholamines and brain natriuretic peptide (BNP).
lasma noradrenaline concentration was measured with
igh-performance liquid chromatography (BML Co., Ltd.,
okyo, Japan), and plasma BNP concentration was mea-
ured with a chemiluminescent enzyme immunoassay using
commercially available kit (Pathfast, Mitsubishi Chemical
edience Co., Ltd., Tokyo, Japan), at admission and 4 weeks
fter treatment.
easurement and evaluation of the autonomic
ervous systemhe indices of HRV can be divided into two major categories:
ime and frequency domain indices. We calculated the time
omain index using the coefﬁcient of variation of RR inter-
als (CVRR), which was determined by dividing the standard





aB, angiotensin II receptor blocker; DCM, dilated cardiomyopathy;
or a 5-min recording of the electrocardiogram at rest. Thus,
VRR, an index of parasympathetic nervous activity, was cal-
ulated as follows: CVRR (%) = (SD/M)× 100 [25]. In addition,
e analyzed the frequency domain index to assess the mag-
itude of the individual components of the heart rate power
pectrum. Three main spectral components are distin-
uished in a spectrum calculated from short-term recording
f 2 to 5min: very-low-frequency (VLF; 0.003—0.04Hz),
ow-frequency (LF; 0.04—0.15Hz), and high-frequency com-
onents (HF; 0.15—0.40Hz) [7,26]. We analyzed consecutive
R intervals in order to assess both LF and HF of the
eart rate power spectrum using the MemCalc/Tonam® sys-
em (Suwa Trust, Tokyo, Japan) [27—29]. Normalized units
nu) were calculated from the following equations: LF
orm= LF/(LF +HF), and HF norm=HF/(LF +HF) [7]. The HF
lement and HF norm reﬂect only parasympathetic nervous
ctivity, because the HF element is not reduced by sympa-
hetic blockade with propranolol, but rather is abolished by
agal blockade with atropine [30—32]. In contrast, the LF/HF
atio and LF norm are generally used as indices of sympa-
hetic nervous activity, because the LF element reﬂects both
ympathetic and parasympathetic nervous activity [29,32].
ime domain analysis and spectral analysis of HRV were per-
ormed for a consecutive 5-min period in this study. HRV
as been shown to be inﬂuenced by various conditions such
s circadian rhythm, room temperature, physical and men-
al stress, body position, eating, smoking, and sleeping.
herefore, we prohibited the subjects from intense exer-
ise, smoking, and alcohol drinking during hospitalization,
nd prohibited them from eating for 3 h before the mea-
urement. HRV was measured in a quiet and air-conditioned
oom. We also measured HRV after at least 15min of rest
n the supine position and at the same time each day
o avoid the inﬂuence of circadian rhythm. In the Waon
herapy group, HRV was measured at 6 h after Waon ther-
py.
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Table 2 Parameters at admission and after 4 weeks in the Waon therapy and control groups.
Variable Control group (n = 27) Waon therapy group (n = 27) Comparison between groups
Admission After 4 weeks Admission After 4 weeks Admission After 4 weeks
Body weight (kg) 58 ± 15 57 ± 14*** 57 ± 10 56 ± 11*** 0.63 0.69
SBP (mmHg) 106 ± 18 103 ± 16* 106 ± 20 100 ± 17*** 0.95 0.62
DBP (mmHg) 65 ± 9 62 ± 10* 65 ± 10 62 ± 10 0.89 0.88
HR (beat/min) 71 ± 11 68 ± 10 72 ± 14 67 ± 10* 0.91 0.82
CTR (%) 58 ± 5 56 ± 5*** 57 ± 4 54 ± 5*** 0.17 0.11
CO (l/min) 3.12 ± 0.71 3.06 ± 0.73 2.88 ± 0.71 3.18 ± 0.72* 0.34 0.44
LVEF (%) 31 ± 9 32 ± 11 33 ± 13 35 ± 12* 0.47 0.31
LVEDV (ml) 194 ± 47 191 ± 59 179 ± 63 164 ± 59* 0.35 0.10
LV-Tei index 0.75 ± 0.21 0.80 ± 0.23 0.81 ± 0.32 0.79 ± 0.28 0.41 0.84
RV-Tei index 0.69 ± 0.23 0.56 ± 0.22** 0.67 ± 0.40 0.54 ± 0.28* 0.87 0.71
BNP (pg/ml) 522 ± 234 387 ± 314** 521 ± 439 278 ± 213*** 0.99 0.14
Noradrenaline (pg/ml) 626 ± 443 472 ± 220 673 ± 396 436 ± 177** 0.76 0.54
Values are means± SD; BNP, brain natriuretic peptide; CO, cardiac output; CTR, cardiothoracic ratio; DBP, diastolic blood pressure; HR,
heart rate; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; RV, right ventricle;



























W* p < 0.05 vs. admission.
** p < 0.01 vs. admission.
*** p < 0.001 vs. admission.
Statistics
Statistical analysis was performed using Stat View Ver-
sion 5.0 software. Values are expressed as the mean± SD.
Comparisons of data between the two groups were per-
formed using Pearson’s 2-test or Student’s unpaired t-test.
Within-group changes between admission and 4 weeks after
treatment were evaluated by paired t-test. Statistical sig-
niﬁcance was accepted when the p-value was < 0.05.
Results
Clinical characteristics at admission
The clinical characteristics of patients at admission are
shown in Table 1. There were no signiﬁcant differences
in age, gender, NYHA functional class, etiology of heart
failure, complications, or the use of medications between
the two groups at admission. We used three beta-blockers
such as carvedilol, atenolol, and metoprolol. The dosage
of atenolol and metoprolol were converted into that of
carvedilol, and there was no signiﬁcant difference in dosage
of beta-blockers at admission between the two groups
(Waon therapy group: 4.5± 3.5mg/day vs. control group:
3.4± 3.5mg/day).
In addition, as shown in Table 2, there were no signif-
icant differences in body weight, systolic blood pressure,
diastolic blood pressure, mean heart rate, plasma BNP, and
noradrenaline levels, CTR, or echo-derived measures such
as CO, LVEF, LVEDV, LV-Tei index, and RV-Tei index between
the two groups at admission.Clinical ﬁndings and physical examinations
The changes in the clinical ﬁndings and variables after 4
weeks are summarized in Table 2. Body weight and sys-





treatment compared with admission in both groups. Dias-
olic blood pressure signiﬁcantly decreased in the control
roup after 4 weeks compared with admission, but did not
hange in the Waon therapy group. Mean heart rate signif-
cantly decreased in the Waon therapy group after 4 weeks
ompared with admission, but did not change in the con-
rol group. There were no signiﬁcant differences in these
arameters between the two groups after 4 weeks.
hest radiography and echocardiography
hanges in chest radiography and echocardiography are also
hown in Table 2. Chest radiography showed a signiﬁcant
ecrease of the CTR at 4 weeks after treatment compared
ith admission in both groups. In addition, echocardiogra-
hy demonstrated that CO, LVEF, LVEDV, and RV-Tei index
igniﬁcantly improved after 4 weeks in the Waon therapy
roup, but LV-Tei index did not change after Waon therapy. In
he control group, only RV-Tei index signiﬁcantly decreased
fter 4 weeks, but CO, LVEF, LVEDV, and LV-Tei index did not
hange after treatment. There were no signiﬁcant differ-
nces in any of these indices between the two groups after
weeks.
lasma levels of BNP and noradrenaline
s shown in Table 2, the plasma levels of BNP signiﬁcantly
ecreased 4 weeks after treatment compared with admis-
ion in both groups. There was no signiﬁcant difference in
NP levels between the two groups after 4 weeks. In the
aon therapy group, plasma noradrenaline levels signiﬁ-
antly decreased 4 weeks after Waon therapy. In the control
roup, plasma noradrenaline levels tended to decrease after
weeks, but did not reach statistical signiﬁcance. There was
o signiﬁcant difference in noradrenaline levels between the
wo groups after 4 weeks.
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Analysis of the autonomic nervous system
Changes in the indices of parasympathetic nervous activ-
ity such as HF, HF norm, and CVRR are shown in
Figs. 1—3. In the Waon therapy group, HF, HF norm, and
Figure 1 Changes in parasympathetic nervous function
demonstrated by HF after 4 weeks of treatment. HF, high-
frequency component.
Figure 2 Changes in parasympathetic nervous function
demonstrated by HF norm after 4 weeks of treatment. HF
norm=normalized HF =HF/(LF +HF); HF, high-frequency com-
ponent; LF, low-frequency component.
Figure 3 Changes in parasympathetic nervous function
demonstrated by CVRR after 4 weeks of treatment. CVRR, coef-
ﬁcient of variation of RR intervals.
CVRR signiﬁcantly increased 4 weeks after Waon ther-
apy (HF: 81± 78 to 164± 118ms2, p = 0.004; HF norm:
0.47± 0.21 to 0.56± 0.16 nu, p = 0.019; CVRR: 1.29± 0.59
to 1.70± 0.67%, p = 0.011). In contrast, these parameters
remained unchanged in the control group (HF: 95± 95 to
98± 93ms2, p = 0.86; HF norm: 0.48± 0.17 to 0.44± 0.12 nu,
p = 0.31; CVRR: 1.56± 0.80 to 1.49± 0.78%, p = 0.72). More-
over, the HF and HF norm after 4 weeks in the Waon therapy
group were signiﬁcantly higher than those in the control
group (HF: p = 0.025; HF norm: p = 0.004).
Changes in the indices of sympathetic nervous activ-
ity such as the LF/HF ratio and LF norm are shown in
Figs. 4 and 5. In the Waon therapy group, the LF/HF
ratio and LF norm signiﬁcantly decreased 4 weeks after
Waon therapy (LF/HF: 2.31± 2.03 to 1.20± 0.93, p = 0.001;
LF norm: 0.53± 0.21 to 0.44± 0.16 nu, p = 0.019). In con-
trast, these parameters remained unchanged in the control
group (LF/HF: 2.06± 1.90 to 1.85± 1.15, p = 0.56; LF norm:
0.52± 0.17 to 0.56± 0.12 nu, p = 0.31). Moreover, the LF/HF
ratio and LF norm after 4 weeks in the Waon therapy group
were signiﬁcantly lower than those in the control group
(LF/HF ratio: p = 0.013, LF norm: p = 0.004).
Figure 4 Changes in sympathetic nervous function demon-
strated by the LF/HF ratio after 4 weeks of treatment. HF,
high-frequency component; LF, low-frequency component.
Figure 5 Changes in sympathetic nervous function demon-
strated by LF norm after 4 weeks of treatment. LF
norm=normalized LF = LF/(LF +HF); HF, high-frequency compo-
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Discussion
The major novel ﬁnding of the current study is that repeated
Waon therapy improved cardiac autonomic nervous activ-
ity in CHF patients. Several mechanisms may contribute to
the improvement of autonomic nervous activity by Waon
therapy. In acute heart failure, heart rate will rise through
arterial baroreﬂex-mediated vagal withdrawal and sym-
pathetic activation to maintain CO. In addition, there is
an inverse relationship between muscle sympathetic nerve
burst frequency and hemodynamic variables, such as LV
stroke-work index and stroke-volume index, and a direct
correlation with atrial, pulmonary artery, and LV ﬁlling pres-
sures [33]. Indeed, Waon therapy signiﬁcantly improved
CO, LVEF, and LVEDV in this study. Moreover, we previously
reported that cardiac and stroke volume index increased
and systemic vascular resistance decreased signiﬁcantly dur-
ing and after Waon therapy [10]. Furthermore, we also
reported signiﬁcant decreases in mean pulmonary artery,
mean pulmonary capillary wedge, and mean right atrial
pressures during Waon therapy [10]. These reductions in
cardiac preload and afterload, and an increase in CO are
attributable to the improvement of autonomic nervous
activity.
Interestingly, mean heart rate signiﬁcantly decreased
in only the Waon therapy group. As heart failure pro-
gresses inhibitory input from arterial and cardiopulmonary
receptors decreases and excitatory input increases. The
net response to this altered balance includes a general-
ized increase in sympathetic nerve trafﬁc, and blunted
parasympathetic and sympathetic control of heart rate
[4].
It is widely recognized that nitric oxide (NO), which
largely accounts for the biological effects of endothelium-
derived relaxing factor, is an important regulator of vascular
function. The nitric oxide synthase (NOS) system plays salu-
tary roles in a variety of cardiovascular diseases in mice [34].
Young et al. [35] reported that pharmacological inhibition
of NOS causes sympathetic activation, and NO is involved in
the regulation of sympathetic nervous activity in humans. In
this regard, we previously demonstrated that Waon therapy
improves endothelial function [11,36] and increases mRNA
expression and protein levels of endothelial nitric oxide syn-
thase (eNOS) in the aorta of Syrian golden hamsters [37]
and TO-2 cardiomyopathic hamsters [38]. Thus, the improve-
ment in endothelial function and increased eNOS expression
by Waon therapy may lead to the normalization of autonomic
nervous activity.
Study limitations
Some limitations of this study should be considered when
interpreting the results. First, because the number of par-
ticipating patients was small, the statistical power of the
study to discern signiﬁcant differences between the two
treatment groups was reduced. Second, diabetic patients
were included in both groups. Although diabetic neuropathy
causes autonomic nervous dysfunction [39], the percentage
of diabetic patients did not differ between the two groups
in the current study.
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onclusions
epeated Waon therapy improved cardiac function and nor-
alized cardiac autonomic nervous activity by increasing
arasympathetic and decreasing sympathetic nervous activ-
ty in CHF patients. Waon therapy is an innovative and
romising nonpharmacological treatment for CHF.
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